星昊医药
(430017)
| 流通市值：16.78亿 | | | 总市值：16.95亿 |
| 流通股本：1.21亿 | | | 总股本：1.22亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 468,292,733.23 | 321,401,139.92 | 154,300,499.21 | 721,995,870.96 |
| 营业收入 | 468,292,733.23 | 321,401,139.92 | 154,300,499.21 | 721,995,870.96 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 411,245,882.53 | 275,641,314.58 | 135,989,341.13 | 657,118,679.52 |
| 营业成本 | 143,378,676.55 | 95,847,536.79 | 40,638,493.25 | 186,793,336.05 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 提取保险合同准备金净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 5,290,109.06 | 3,852,766.03 | 1,318,632.98 | 10,624,563.27 |
| 销售费用 | 173,411,913.91 | 117,552,272 | 65,388,168.62 | 325,539,875.73 |
| 管理费用 | 35,149,124.75 | 23,821,358.28 | 12,837,828.63 | 65,618,572.75 |
| 研发费用 | 57,186,846.22 | 37,460,384.88 | 17,909,848.02 | 73,184,198.6 |
| 财务费用 | -3,170,787.96 | -2,893,003.4 | -2,103,630.37 | -4,641,866.88 |
| 其中:利息费用 | 178,691.82 | 110,971.21 | 59,402.78 | 127,292.67 |
| 其中:利息收入 | 3,657,102.48 | 3,241,790.19 | 2,188,310.89 | 4,843,023.06 |
| 加:公允价值变动收益 | 3,308,786.3 | 3,533,261.66 | 2,426,856.18 | 2,296,560.29 |
| 加:投资收益 | 8,397,475.69 | 2,533,934.5 | 303,459.89 | 9,175,626.9 |
| 净敞口套期收益 | - | - | - | 0 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | - | - | 0 | 132,519.41 |
| 资产减值损失(新) | -464,095.89 | -235,057.74 | 103,724.2 | -1,286,909.96 |
| 信用减值损失(新) | -648,125.71 | -548,843.92 | -295,661.57 | -1,424,332.1 |
| 其他收益 | 17,523,192.75 | 12,219,764.43 | 4,749,697.03 | 32,605,729.55 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 85,164,083.84 | 63,262,884.27 | 25,599,233.81 | 106,376,385.53 |
| 加:营业外收入 | 1,832,357.96 | 1,815,930.43 | 1,499.99 | 412,889.51 |
| 减:营业外支出 | 141,970.5 | 23,391.16 | 23,160.9 | 3,890,160.86 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 86,854,471.3 | 65,055,423.54 | 25,577,572.9 | 102,899,114.18 |
| 减:所得税费用 | 9,334,386.58 | 5,847,429.73 | 1,375,003.02 | 12,847,861.41 |
| 六、净利润 | 77,520,084.72 | 59,207,993.81 | 24,202,569.88 | 90,051,252.77 |
| 其中:被合并方在合并前实现利润 | - | - | - | 0 |
| 持续经营净利润 | 77,520,084.72 | 59,207,993.81 | 24,202,569.88 | 90,051,252.77 |
| 终止经营净利润 | - | - | - | 0 |
| 归属于母公司股东的净利润 | 78,770,148.31 | 60,428,636.94 | 24,952,836.79 | 92,723,545.76 |
| 少数股东损益 | -1,250,063.59 | -1,220,643.13 | -750,266.91 | -2,672,292.99 |
| (一)基本每股收益 | 0.64 | 0.49 | 0.2 | 0.84 |
| (二)稀释每股收益 | 0.64 | 0.49 | 0.2 | 0.84 |
| 八、其他综合收益 | -1,208.49 | 852.71 | 226.41 | -476,778.19 |
| 归属于母公司股东的其他综合收益 | -1,208.49 | 852.71 | 226.41 | -476,778.19 |
| 九、综合收益总额 | 77,518,876.23 | 59,208,846.52 | 24,202,796.29 | 89,574,474.58 |
| 归属于母公司股东的综合收益总额 | 78,768,939.82 | 60,429,489.65 | 24,953,063.2 | 92,246,767.57 |
| 归属于少数股东的综合收益总额 | -1,250,063.59 | -1,220,643.13 | -750,266.91 | -2,672,292.99 |
| 公告日期 | 2024-10-28 | 2024-08-26 | 2024-04-26 | 2024-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |